Latest Commercialization News

Bellavista Resources Ltd has agreed to acquire up to 80% of the Pickle Crow Gold Project in Ontario, Canada, adding a 2.8 million ounce inferred gold resource at 7.2g/t to its portfolio. The company is raising A$25 million to fund aggressive exploration and development activities.

Estrella Resources has entered a $2 million underwriting agreement to support the exercise of its listed options, ensuring capital inflow ahead of the December expiry.

Actinogen Medical has raised approximately $17 million through a share placement and purchase plan to fund the completion of its pivotal XanaMIA Alzheimer’s trial following encouraging interim results.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Axel REE Limited's latest magnesium sulphate leach tests at the Paraíso target confirm robust rare earth grades and a magnet-rich basket, underpinning a modular in-situ leach development at the Caladão Project in Brazil.

Corporate Travel Management's founder Jamie Pherous retires, handing over leadership to Ana Pedersen as the company navigates accounting challenges and aims to relist on the ASX.

FortifAI Limited has completed its acquisition of FastAI Pty Ltd, gaining control of the innovative Nol8 technology and appointing seasoned executive Yosef Keret as director and Celerriem CEO.

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.

Genetic Signatures has appointed Maria Halasz as its new CEO, bringing over two decades of leadership in life sciences and capital markets to steer the company’s global expansion.

Pivotal Metals has revealed ore sorting test results at its Horden Lake project that deliver up to a 2.1 times uplift in copper grade, promising substantial cost savings and flexible development options in Quebec’s Tier 1 mining jurisdiction.